MLLT10: A Protein Targeted for Drug and Biomarker Development

Target Name: MLLT10

NCBI ID: G8028

MLLT10

MLLT10: A Protein Targeted for Drug and Biomarker Development

MLLT10 (MLLT10 variant 3) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the MLLT family of proteins, which are known for their role in the development and maintenance of the blood-brain barrier. MLLT10 plays a crucial role in this process, as it helps to ensure that certain proteins cannot reach the brain and cause neurotoxicity.

MLLT10 is also known for its role in the regulation of cell death. When a cell is damaged or has been cleared of its contents, MLLT10 helps to ensure that it is properly disposed of and that the body can begin the process of repair. This is important for maintaining the health and function of the body's cells.

One of the things that makes MLLT10 so interesting as a drug target is its ability to interact with a wide range of molecules. This makes it a promising candidate for a variety of different treatments, including those that are designed to protect or repair damaged cells.

One of the ways that MLLT10 may be used to treat damaged cells is by inhibiting its activity. This could be done using small molecules, such as drugs that bind to MLLT10 and prevent it from interacting with its target proteins. Alternatively, MLLT10 could be targeted directly using antibodies that recognize and label the protein.

Another potential way to use MLLT10 as a drug target is to activate its activity. This could be done by using drugs that stimulate MLLT10, such as those that bind to its surface and cause it to become more active. This could be useful for treating diseases where cells are not functioning properly, such as neurodegenerative disorders.

MLLT10 is also worth studying as a potential biomarker. Its role in the regulation of cell death and its interaction with a wide range of molecules make it an attractive candidate for use as a diagnostic or therapeutic target. This could be done using a variety of techniques, including mass spectrometry and biochemical assays.

Overall, MLLT10 is a protein that is worth studying further as a potential drug target or biomarker. Its ability to interact with a wide range of molecules and its role in the regulation of cell death make it a promising candidate for a variety of different treatments. Further research is needed to fully understand its potential and to develop safe and effective therapies based on it.

Protein Name: MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor

Functions: Probably involved in transcriptional regulation. In vitro or as fusion protein with KMT2A/MLL1 has transactivation activity. Binds to cruciform DNA. In cells, binding to unmodified histone H3 regulates DOT1L functions including histone H3 'Lys-79' dimethylation (H3K79me2) and gene activation (PubMed:26439302)

The "MLLT10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MLLT10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets